-

Bruker Demonstrates Novel and Unique Compact 1.0 GHz NMR Magnet

New Innovations Support Customers to Reduce Liquid Helium Consumption

ORLANDO, Fla.--(BUSINESS WIRE)--At the Experimental Nuclear Magnetic Resonance Conference (ENC 2022), Bruker demonstrates a novel and remarkably compact 1.0 GHz NMR magnet, operating at 4.2 Kelvin, for structural biology applications in single-story standard laboratories. Bruker also offers innovations and services for reducing liquid helium consumption.

A major innovation and technology introduction from Bruker is the recent successful factory energization and protein NMR testing of a unique single-story 1.0 GHz 4K NMR magnet, called Ascend Evo 1.0 GHz. Its significantly reduced footprint, weight, and ceiling height requirements, as well as a dramatic threefold reduction in liquid helium consumption provides many more structural biology researchers access to the sensitivity and resolution of GHz NMR. At ENC, Bruker is showing excellent protein 1.0 GHz NMR data from this new and unique technological marvel.

A second innovation is the limited release of the new Heliosmart Recovery solution, a compact, easy-to-site system that can be retrofitted to collect helium gas boil-off from installed NMR magnets. The helium gas is stored in high-pressure cylinders in support of a circular helium economy. The Heliosmart Recovery system can collect the normal boil-off of several NMR magnets, resulting in typical steady-state recovery rates of 80% – 85%. The recovered high-pressure helium gas can be utilized at local or regional helium reliquefaction facilities.

Bruker offers free LabScape Remote Monitoring, which enables our experts to proactively monitor magnets and identify upcoming cryogen refills that can be scheduled well in advance. Bruker also offers helium refills as a service with selected NMR maintenance service agreements.

Dr. Falko Busse, President of the Bruker BioSpin Group, commented: “We are extremely pleased to demonstrate the world’s first single-story 1.0 GHz standard-bore 4 Kelvin NMR magnet, and we are committed to reducing the consumption of liquid helium with our latest innovations.”

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph. D.
VP of Group Marketing, Bruker BioSpin
T: +49 (721) 5161–6500
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)--At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by...

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit...

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

SAN DIEGO--(BUSINESS WIRE)--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus...
Back to Newsroom